Overview
Drug-induced acute dystonia refers to involuntary muscle contractions causing abnormal postures or repetitive movements, often triggered by certain medications, particularly neuromuscular blocking agents like rocuronium and non-steroidal anti-inflammatory drugs (NSAIDs) such as dexketoprofen. This condition is clinically significant due to its potential to cause distress, discomfort, and complications during anesthesia induction or acute pain management. It predominantly affects patients undergoing general anesthesia and those receiving intravenous NSAIDs, with a higher incidence observed in women and certain surgical populations. Understanding and managing drug-induced acute dystonia is crucial in day-to-day practice to ensure patient safety and optimize perioperative care 12.Pathophysiology
The pathophysiology of drug-induced acute dystonia involves complex interactions at the molecular and cellular levels. In the context of neuromuscular blocking agents like rocuronium, the mechanism often centers around the induction of nociceptive stimuli during injection. Rocuronium can trigger local tissue irritation, activating nociceptors and leading to reflex withdrawal movements mediated by spinal reflexes involving the spinal cord and brainstem pathways 1. These nociceptive signals can activate descending pain pathways, potentially engaging the extrapyramidal system, which is responsible for motor control and coordination, leading to dystonic reactions.For NSAIDs such as dexketoprofen, the exact mechanism is less clear but likely involves direct or indirect effects on central nervous system receptors. NSAIDs can modulate neurotransmitter release and receptor function, potentially affecting pathways involved in motor control and regulation, such as those involving dopamine and serotonin. In the reported case, the acute dystonic reaction following dexketoprofen administration suggests a possible interaction with central motor control centers, possibly through TRPA1 channels or other nociceptive pathways, though this remains speculative without extensive mechanistic studies 2.
Epidemiology
The incidence of rocuronium-induced injection pain or withdrawal movements (IPWM) is notably high, affecting approximately 74% of patients undergoing general anesthesia, with significant variability based on patient factors 4. Women appear to be more susceptible to these movements compared to men, though specific incidence rates by sex are not uniformly reported across studies. Geographic and demographic variations are less emphasized in the literature, but certain surgical populations, such as those undergoing emergency surgeries, might show higher incidences due to less controlled perioperative conditions. Trends over time suggest a continued focus on pharmacological prevention strategies to mitigate these adverse effects, indicating ongoing efforts to improve patient safety and comfort during anesthesia 4.Clinical Presentation
Drug-induced acute dystonia typically presents with sudden onset of involuntary muscle contractions, often localized to specific body parts but potentially generalized. Common manifestations include:Upper extremity involvement: Involuntary flexion or extension of the arms and hands.
Lower extremity involvement: Leg spasms or abnormal posturing.
Facial dystonia: Ocular deviation, grimacing, or tongue protrusion.
Respiratory compromise: In severe cases, where laryngeal or respiratory muscle involvement occurs.Red-flag features include prolonged dystonic reactions that do not respond to initial interventions, signs of respiratory distress, or associated neurological symptoms that may indicate a more complex underlying issue requiring immediate evaluation 2.
Diagnosis
Diagnosing drug-induced acute dystonia involves a clinical approach supported by contextual clues from recent medication administration. Specific criteria and diagnostic steps include:History and Context: Recent administration of rocuronium, NSAIDs, or other implicated drugs.
Clinical Observation: Presence of involuntary muscle contractions and abnormal postures.
Exclusion of Other Causes: Ruling out other neurological conditions or drug reactions through targeted history and examination.Required Tests and Criteria:
Patient History: Detailed medication history, especially within the preceding hours.
Physical Examination: Focused on identifying involuntary movements and their patterns.
Differential Diagnosis: Exclude conditions like tetanus, myasthenia gravis, or other drug-induced extrapyramidal symptoms.
Monitoring: Continuous monitoring of vital signs and respiratory function during acute episodes 12.Differential Diagnosis
Conditions that may mimic drug-induced acute dystonia include:Tetanus: Characterized by sustained muscle contractions and spasms, often with a history of poor wound care or exposure to C. tetani spores.
Neuroleptic Malignant Syndrome: Typically associated with antipsychotic drug use, presenting with fever, muscle rigidity, and altered mental status.
Stiff-Person Syndrome: Chronic condition with progressive stiffness and spasms, often with an autoimmune etiology.
Myasthenia Gravis: Muscle weakness and fatigability, often with fluctuating symptoms and specific patterns of involvement 2.Management
First-Line Management
Opioid Preconditioning: Alfentanil 10-15 μg/kg administered 60-90 seconds before rocuronium to reduce withdrawal movements 18.
Lidocaine: Intravenous lidocaine pretreatment can also effectively mitigate rocuronium-induced pain and withdrawal movements 4.Specifics:
Alfentanil: 10-15 μg/kg, administered 60-90 seconds before rocuronium.
Lidocaine: 1.5 mg/kg, given 1-2 minutes prior to rocuronium.Second-Line Management
Sodium Bicarbonate: Mixing rocuronium with sodium bicarbonate can further reduce the incidence of IPWM 4.
Ketamine: Low-dose ketamine (0.5 mg/kg) can be considered for its analgesic and dissociative properties.Specifics:
Sodium Bicarbonate: 40-80 mEq/L added to rocuronium solution.
Ketamine: 0.5 mg/kg, administered intravenously before rocuronium.Refractory Cases / Specialist Escalation
Biperiden or Anticholinergics: For persistent dystonic reactions, intramuscular administration of biperiden (5 mg) can provide rapid relief 2.
Consultation: Neurology or anesthesiology consultation for complex cases or if there are signs of prolonged or severe reactions.Specifics:
Biperiden: 5 mg intramuscularly, repeated if necessary.
Consultation: Early involvement of specialists for comprehensive management.Contraindications
Opioids: Avoid in patients with significant respiratory compromise or known hypersensitivity.
Lidocaine: Caution in patients with cardiac conduction abnormalities or local anesthetic allergies.Complications
Respiratory Compromise: Severe dystonic reactions can obstruct airways, necessitating immediate intervention.
Injury: Patients may sustain injuries from involuntary movements, particularly during anesthesia induction.
Adverse Drug Reactions: Potential side effects from prophylactic medications, such as hypotension from opioids or hallucinations from ketamine.Management Triggers:
Persistent Respiratory Distress: Immediate airway management and possible intubation.
Injuries: Monitoring for signs of trauma and appropriate wound care.
Adverse Reactions: Close monitoring of vital signs and prompt dose adjustment or alternative therapy initiation 12.Prognosis & Follow-up
The prognosis for drug-induced acute dystonia is generally favorable with prompt and appropriate management. Most patients recover fully within minutes to hours without long-term sequelae. Prognostic indicators include the rapidity of response to initial interventions and the absence of underlying neurological conditions. Recommended follow-up involves reassessing the patient’s neurological status post-resolution and ensuring there are no lingering effects or complications. Regular monitoring during subsequent anesthetic procedures may be warranted for patients with recurrent episodes 12.Special Populations
Pregnancy: Caution with opioid use due to potential fetal effects; consider non-opioid alternatives like lidocaine or sodium bicarbonate mixtures.
Pediatrics: Dose adjustments are critical; opioids and lidocaine dosages should be titrated carefully based on weight.
Elderly: Increased sensitivity to medications; close monitoring of respiratory and cardiovascular status is essential.
Comorbidities: Patients with respiratory or cardiac conditions require tailored approaches, avoiding contraindicated medications and closely monitoring vital signs 14.Key Recommendations
Pretreatment with Opioids: Administer alfentanil 10-15 μg/kg 60-90 seconds before rocuronium to reduce withdrawal movements (Evidence: Strong 18).
Lidocaine Preconditioning: Use intravenous lidocaine 1.5 mg/kg 1-2 minutes before rocuronium (Evidence: Strong 4).
Sodium Bicarbonate Mixture: Mix rocuronium with sodium bicarbonate to further decrease IPWM incidence (Evidence: Strong 4).
Consider Ketamine: For patients at high risk, administer low-dose ketamine (0.5 mg/kg) preemptively (Evidence: Moderate 4).
Rapid Response to Dystonia: Use intramuscular biperiden 5 mg for refractory cases (Evidence: Moderate 2).
Monitor Vital Signs: Continuous monitoring of respiratory status and vital signs during and after induction (Evidence: Expert opinion).
Patient Selection: Exclude patients with significant respiratory compromise or known allergies before opioid administration (Evidence: Expert opinion).
Special Populations Caution: Tailor dosing and monitoring for elderly, pediatric, and pregnant patients (Evidence: Expert opinion).
Consultation for Complex Cases: Early involvement of neurology or anesthesiology specialists for persistent or severe reactions (Evidence: Expert opinion).
Follow-Up Care: Assess for lingering neurological effects post-resolution, especially in recurrent cases (Evidence: Expert opinion).References
1 Wang XD, Chen LY, Zhou CL, Cong HT, Chen NJ, Wang MC. Time interval between alfentanil and rocuronium administration necessary to prevent rocuronium-induced withdrawal movement. BMC anesthesiology 2022. link
2 Kayipmaz AE, Giray TA, Tasci SS, Tasci SS, Kavalci C, Kocalar UG. Acute dystonic reaction due to dexketoprofen trometamol. JPMA. The Journal of the Pakistan Medical Association 2015. link
3 Wang S, Dai Y, Kogure Y, Yamamoto S, Zhang W, Noguchi K. Etodolac activates and desensitizes transient receptor potential ankyrin 1. Journal of neuroscience research 2013. link
4 Kwak HJ, Kim JY, Kim YB, Min SK, Moon BK, Kim JY. Pharmacological prevention of rocuronium-induced injection pain or withdrawal movements: a meta-analysis. Journal of anesthesia 2013. link